Fruquintinib

Brand Name: Fruzaqla

Manufacturer: Takeda Canada Inc.

Indication

Indication

For the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-tipiracil or regorafenib.

Specific CRC Subtype: None

Stage: IV

Therapy Line: Third-line or later

Health Canada Approval: Approved

pCPA Negotiation Status: Completed

Reimbursed in: AB (Alberta), BC (British Columbia), NS (Nova Scotia), QC (Quebec), SK (Saskatchewan)

New Search